1 Min Read
Nov 17 (Reuters) - ProMetic Life Sciences Inc
* ProMetic’s PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis (“IPF”) phase 2 clinical trial Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.